Brain training instead of medication to counter insomnia

15-Apr-2015 - The ability to finally enjoy a good night's sleep is something that can be learned. An Austrian Science Fund FWF project has investigated how this can best be learned and who responds best to such "brain training". Dark circles around the eyes, tired limbs, absent-mindedness – most people have ...

Researchers Find Link between Persistent Insomnia and Increased Mortality Risk

02-Mar-2015 - A connection between persistent insomnia and increased inflammation and mortality has been identified by a group of researchers from the University of Arizona. Their study, published in The American Journal of Medicine, found that people who suffer from persistent insomnia are at greater risk ...

Do you want to know how much caffeine is in your drink?

09-Aug-2013 - A team of researchers led by Prof. Young-Tae Chang from National University of Singapore and Prof. Yoon-Kyoung Cho from Ulsan National Institute of Science and Technology (UNIST), Korea, developed a fluorescent caffeine detector and a detection kit that lights up like a traffic light when ...

Ferrer announces best-in-class results in phase I for Lorediplon in insomnia

10-Feb-2012 - Ferrer announced that it has completed phase I clinical trials of Lorediplon in insomnia. The trials demonstrated the orally available compound has a best-in-class efficacy profile in terms of sleep maintenance and sleep quality when compared to market leader zolpidem. The pharmacodynamic ...

Evotec licenses Phase II insomnia candidate to Jingxin Pharma for development in China

29-Oct-2010 - Evotec AG announced that it has entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical Co., Ltd ("Jingxin Pharma") for EVT 201, a novel potential treatment for insomnia. The agreement grants Jingxin Pharma exclusive rights to develop and market the drug candidate ...

Circadin is Approved in the EU for Treatment of Primary Insomnia in Patients Aged 55 or Over for up to 3 Months

07-Jul-2010 - Neurim Pharmaceuticals confirmed that the European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months). Circadin is indicated for the treatment of primary insomnia in patients who are aged 55 or over. The approval was based primarily on data ...

New Drug Applications Approval for Five New Products in Japan

20-Apr-2010 - Takeda Pharmaceutical Company Limited announced that New Drug Applications for five new products were approved on April 16 by the Japanese Ministry of Health, Labour and Welfare. Five new products approved for commercial sale in Japan comprise three new medical entities; “NESINA®” for ...

Investigational dual orexin receptor antagonist almorexant meets primary endpoint in phase III study

Evidence for differentiation from traditional GABA-agonist zolpidem observed

23-Dec-2009 - Actelion Ltd announced that the first phase III study with almorexant (RESTORA 1) has met its primary endpoint, superiority of the dual orexin receptor antagonist almorexant compared to placebo on objective and subjective wake after sleep onset (WASO). The finding was highly significant ...

Jazz Pharmaceuticals and UCB announce Phase III study of sodium oxybate in patients with fibromyalgia meets primary endpoints

25-Jun-2009 - Jazz Pharmaceuticals, Inc. and UCB announced positive preliminary top-line results from the second of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. Confirming the positive results from the first Phase III study, this international, placebo-controlled ...

IMS Health Lowers 2009 Global Pharmaceutical Market Forecast to 2.5 – 3.5 Percent Growth

U.S. market to decline in 2009

29-Apr-2009 - IMS Health reported that the value of the global pharmaceutical market is expected to grow 2.5 - 3.5 percent on a constant-dollar basis in 2009, two percentage points lower than indicated last October, as deterioration in the global economic environment continues to affect market demand. The ...